Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T50) is...

Full description

Bibliographic Details
Main Authors: Iain Bressendorff, Ditte Hansen, Morten Schou, Burton Silver, Andreas Pasch, Pierre Bouchelouche, Lise Pedersen, Lars Melholt Rasmussen, Lisbet Brandi
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:Kidney International Reports
Subjects:
calcification propensity
chronic kidney disease
magnesium
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024916301954

Internet

http://www.sciencedirect.com/science/article/pii/S2468024916301954

Similar Items